Amyloid_Beta_Plaque

Amyloid_Beta_Plaque

Two clinical trials of a potential Alzheimer’s drug were halted this week, highlighting circulating skepticism about the hypothesis that amyloid beta plaque is a major factor in the disease’s genesis.

But, as the causes—and a cure—for the disease remain unknown, some researchers suspect that “our current views may be too simplistic,” P. Murali Doraiswamy, head of Biological Psychiatry at Duke University, told The New York Times. And with 115.4 million people estimated to have the disease worldwide by 2050, the urgency to find an effective treatment continues to grow.

The Lilly drug under tests in the Phase III clinical trials was a gamma secretase inhibitor, which had been shown to decrease the amount of amyloid in sampled cerebral spinal fluid, Reuters reported

Advertisements